Skip to main content
Premium Trial:

Request an Annual Quote

ValiGen Signs 5-Year Subscription Deal with Celera

NEW YORK, Sept 28 - ValiGen has signed a five-year deal to subscribe to all of Celera Genomic’s (NYSE: CRA) database products, the companies said Thursday.

Valigen, of Newton, PA, said it would access the databases through Celera’s web-based Discovery System.

Financial terms of the deal were not disclosed.

" This agreement is the first to provide a biotechnology company of our size with access to all of Celera's databases,” Douglas Watson, president and CEO of ValiGen, said in a statement. “This agreement will allow ValiGen to make optimal use of its integrated functional genomics platform and will thereby enhance and accelerate our capabilities to identify and validate intervention targets.”

Under the terms of the deal ValiGen’s researchers will have access to all databases developed by Celera. These databases consist of the Celera Human Gene Index, Human Genome Database, Drosophila Genome Database, Mouse Genome Database, and the SNP Reference Database.

ValiGen conducts research to profile phenotypes, conduct in vivo validation of targets, and to develop human healthcare, plant, and industrial products.

Shares of Celera were up 1 5/8, or 1.6 percent, at 100 3/4 in morning trading.

 

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.